Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 17, 2021 in Coronary artery disease | 0 comments

In a nutshell

This study looked at the use of colchicine (Colcrys) in patients with coronary artery disease (CAD). It found that colchicine reduced the risk of heart attack and stroke in these patients. 

Some background

CAD is a condition affecting the blood vessels in the heart. It leads to narrow or blocked blood vessels. It can lead to heart attacks, stroke or death. CAD is partly caused by inflammation in the blood vessels. Colchicine is an anti-inflammatory medication.

It is not clear if colchicine reduces the risk of heart attack, stroke, or death in patients with CAD.

Methods & findings

This study reviewed the results of 13 studies involving a total of 13,125 patients with CAD. All studies compared standard therapy with colchicine, to standard therapy with or without a placebo.

Compared to standard therapy with or without placebo, colchicine reduced the risk of heart attack by 36%. Colchicine also reduced the risk of stroke by 50%. However, colchicine had no effect on the risk of death, either from heart disease or other causes. Colchicine also increased the risk of stomach upset.

The bottom line

This study showed that adding colchicine to standard therapy in patients with CAD reduced the risk of heart attack and stroke.

The fine print

Studies reviewed in this study used different criteria for assessing outcomes. That makes it difficult to combine the results with absolute certainty. Further studies are needed.

Published By :

Journal of the American Heart Association

Date :

Aug 07, 2021

Original Title :

Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials.

click here to get personalized updates